Akero Therapeutics To Present At Upcoming Conferences In November
SOUTH SAN FRANCISCO, Calif.,
- 29th Annual
Credit Suisse Healthcare Conference onMonday, November 9 th at1:15PM EST Jefferies Global Healthcare Conference onTuesday, November 17 th at1:45PM EST
A live webcast of each presentation and Q&A will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcasts, archived replays will be available on the Company's website.
About
Akero is a cardio-metabolic NASH company dedicated to reversing the escalating NASH epidemic by developing pioneering medicines designed to restore metabolic balance and improve overall health of NASH patients. The Company's lead product candidate, efruxifermin, has been evaluated in a 16-week Phase 2a clinical trial, the BALANCED study.
View original content to download multimedia:http://www.prnewswire.com/news-releases/akero-therapeutics-to-present-at-upcoming-conferences-in-november-301157248.html
SOURCE
Investors, Christina Tartaglia, Stern Investor Relations, Inc., 212.362.1200, christina@sternir.com or Media, Carolyn Hawley, Canale Communications, 619.849.5382, carolyn@canalecomm.com